341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC) Conference Paper

authors

  • Aggarwal, Rahul
  • Costin, Dan
  • Zhang, Jingsong
  • Monk, Paul
  • Linch, Mark
  • Karsh, Lawrence, MD, FACS, CPI
  • Healey, Diane
  • Corsi-Travali, Stefani
  • Adurthi, Sreenivas
  • Adedoyin, Adedayo
  • O’Neill, Vincent

Publication Date

  • 2020

webpage

Digital Object Identifier (DOI)

start page

  • A208

end page

  • A209